Drug Trial Radar · NCT01263015
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Last checked: Nov 20, 2026Latest source record: Apr 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
844
Actual
Start
Feb 1, 2011
Primary completion
May 14, 2012
Study completion Dec 3, 2015
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Shionogi; GlaxoSmithKline
- First posted
- Dec 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48 weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1 infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and development of viral resistance will be evaluated.
Conditions
- Infection, Human Immunodeficiency Virus I
Interventions
DolutegravirDrug
Dolutegravir (also known as GSK1349572) 50 mg taken once daily
AtriplaDrug
Atripla once daily on an empty stomach
Abacavir/LamivudineDrug
taken once daily; also known as EPZICOM
Abacavir/Lamivudine PlaceboDrug
matching placebo taken once daily
Dolutegravir placeboDrug
matching placebo taken once daily
Atripla placeboDrug
matching placebo taken once daily on an empty stomach
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48Time frame: Week 48
Locations
145 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Hobson City, Alabama
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Beach, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Maywood, Illinois
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Springfield, Massachusetts
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Valhalla, New York
GSK Investigational Site
Chapel Hill, North Carolina
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.